FPT-CORPORATION
27.5.2024 09:49:29 CEST | Business Wire | Press release
FPT Corporation (FPT), in collaboration with MEDEF International, Business France, the French Chamber of Commerce and Industry (CCIFV), and French Foreign Trade Advisors (CCE), recently organized the France-Vietnam Business Forum in Paris, France. Gathering leading business leaders and tech experts, the event covered topics aiming at accelerating the economic dynamism between Vietnam and France, targeting core industries of both sides, such as aerospace, automotive, manufacturing, energy, and healthcare.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240527659801/en/
The event was attended by the Vietnamese Ambassador to France, Dinh Toan Thang, Business France, MEDEF International, CCI France Vietnam, French Foreign Trade Advisors, and over 100 high-level government officials, business leaders, and tech experts. (Photo: Business Wire)
“Vietnam is one of France’s main economic partners in Southeast Asia, covering a diverse array of sectors with increasing import of Vietnam’s specialised electronic and textile products. In terms of investment, France is the second largest European (EU) investor in Vietnam, generating 50,000 jobs for this market. In 2023, Business France also supported nine Vietnamese investment projects in France,” said Laurent Saint-Martin, CEO of Business France.
Featuring panelists from global businesses and organizations like NVIDIA, FPT, Egis, Thales, Oerlikon, Valeo, OPmobility, and more, the business forum offered attendees the latest updates in next-gen technology and the national socio-economic outlook. Key topics included the economic attractiveness of France and Vietnam, Vietnam’s momentum as a global digital and investment hub, ethical innovation in artificial intelligence, and smart mobility for a sustainable future.
Throughout the panel discussions, FPT has showcased its broad expertise, industry experience, and extensive global outreach, reaffirming its position as a sustainable transformative enabler with cutting-edge and green technologies.
“Vietnam is emerging as a workforce powerhouse and a global hub for investment and technology, notably in digital transformation and green transition, as well as the advancement of AI and the automotive industry. As the country’s leading corporation, FPT’s strategic directions align with the French government and businesses. We have a robust partnership network, a highly skilled workforce, and a solid global presence to bridge the friendship and cooperation between Vietnam and France’s enterprises,” said Pham Minh Tuan, FPT Executive Vice President and FPT Software CEO.
“FPT is the perfect illustration of what France and Vietnam can achieve together. Their 15 years of presence in France with continuous investments since 2008 have created over 120 jobs and the establishment of three subsidiaries. Their renewed strategic partnership with Airbus in 2021 is also an evident symbol of effective cooperation with the European industrial sector,” Laurent added.
FPT now has over 100 local experts working in France's major cities and 500 offshore professionals in Vietnam, focusing on AI, Big Data, BI, SAP, DevSecOps, Cloud, and AUTOSAR services. Its robust competencies are recognized through strategic partnerships with more than 50 French giants across industries.
As part of the company’s global expansion, FPT has been actively involved in M&A deals to amplify its offshore delivery capabilities and local footprint, notably the recent acquisition of an 80% stake in the French IT consulting firm AOSIS. Last year, its French subsidiary also entered the Top 100 ICT Companies in France, targeting to enter the top 50 by 2028.
About FPT Corporation
FPT Corporation (FPT) is a globally leading technology and IT services provider headquartered in Vietnam. FPT operates in three core sectors: Technology, Telecommunications, and Education. During over three decades of development, FPT has constantly provided practical and effective products to millions of people and tens of thousands of business and non-business organizations worldwide, establishing Vietnam’s position on the global tech map. Keeping up with the latest market trends and emerging technologies, FPT has developed the Made-by-FPT ecosystem of services, products, solutions, and platforms, which enables sustainable growth for organizations and businesses and offers distinctive experiences to customers. In 2023, FPT recorded a total revenue of USD 2.17 billion and 48,000+ employees. For more information, please visit https://fpt.com/en.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240527659801/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom